Impact of COVID ‐19 in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Enrolled in the DELIVER Trial

ConclusionDELIVER is one of the most extensive experiences with COVID-19 of any cardiovascular trial, with>75% of follow-up time occurring during the pandemic. COVID-19 was common, with>50% of cases leading to hospitalization or death. Treatment benefits of dapagliflozin persisted when censoring at COVID-19 diagnosis and pandemic onset. Patients surviving COVID-19 event had a high early residual risk.This article is protected by copyright. All rights reserved.

Source: European Journal of Heart Failure - September 29, 2023 Category: Cardiology Authors: Ankeet S. Bhatt, Mikhail N. Kosiborod, Brian L. Claggett, Zi Michael Miao, Muthiah Vaduganathan, Carolyn S.P. Lam, Adrian F. Hernandez, Felipe A. Martinez, Silvio E Inzucchi, Sanjiv J. Shah, Rudolf A. Boer, Pardeep S. Jhund, Akshay S. Desai, Tags: Research Article Source Type: research